These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 17332569)
21. FDA user fees and innovation. Somberg J Am J Ther; 2008; 15(2):97. PubMed ID: 18356626 [No Abstract] [Full Text] [Related]
22. Vioxx may go back on sale after scraping past FDA panel. Wadman M Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304 [No Abstract] [Full Text] [Related]
23. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
24. Schering-Plough agrees to pay FDA $500 million and bring factories into compliance. Kuehn BM J Am Vet Med Assoc; 2002 Jul; 221(2):174, 180. PubMed ID: 12118571 [No Abstract] [Full Text] [Related]
25. FDA dependence on drug industry. Lawson GW J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677 [No Abstract] [Full Text] [Related]
26. Good law from tragic facts--Congress, the FDA, and preemption. Annas GJ N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383 [No Abstract] [Full Text] [Related]
27. FDA vs. free speech over drug promotions. Anderson C Nature; 1991 Dec; 354(6353):421. PubMed ID: 1749421 [No Abstract] [Full Text] [Related]
28. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say. DerGurahian J Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373 [No Abstract] [Full Text] [Related]
36. Frustrated by regulatory delays at FDA, biotech companies warm to user fees. Gershon D Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553 [No Abstract] [Full Text] [Related]
37. FDA needs more funding, NEJM says, amid questions about antidiabetes drug. Tanne JH BMJ; 2007 Aug; 335(7615):322. PubMed ID: 17703024 [No Abstract] [Full Text] [Related]
38. FDA finalizing policy statement on industry-supported activities. Am J Hosp Pharm; 1993 Mar; 50(3):391. PubMed ID: 8442443 [No Abstract] [Full Text] [Related]
39. Is it possible for FDA regulatory scientists and industry scientists to work together? Woosley RL Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817 [TBL] [Abstract][Full Text] [Related]